Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Lamont applauds Alexion expansion plans

Governor Ned Lamont is applauding an announcement made by Alexion Pharmaceuticals that it plans to invest $10 million to expand its Global Product Development lab...

| By Kelley Gipson

InveniAI expands its flagship platform, AlphaMeld™

InveniAI® Corporation has expanded its flagship platform, AlphaMeld™. This expansion will provide a suite of products to facilitate the democratization of data analysis across the...

| By Kelley Gipson

BioCT welcomes Analoui and Boustany to Board

BioCT welcomes two new members to its Board of Directors. Mostafa Analoui, Ph.D., is Executive Director of Venture Development and Technology Incubation Program (TIP) at...

| By Kelley Gipson

BI wins FDA approval for lung disease medicine

The FDA has approved Boehringer Ingelheim’s Ofev (nintedanib) as the first and only medicine to slow the rate of decline in pulmonary function in patients...

| By Kelley Gipson

SpringWorks announces IPO

SpringWorks Therapeutics reports the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00...

| By Kelley Gipson

Melinta names Sanfillipo interim CEO

Melinta Therapeutics reports that Jennifer Sanfilippo has been named interim chief executive officer and director. Prior to this appointment, Ms. Sanfilippo served as senior vice...

| By Kelley Gipson

ABCT information sessions scheduled

Accelerator for Biosciences in Connecticut, ABCT, is a competitive entry, 6-month long program designed for entrepreneurial research students and faculty, MBA’s and MD’s interested in...

| By Kelley Gipson

Cybrexa names John Houston to board of directors

Cybrexa Therapeutics has appointed John Houston, PhD, to its board of directors. Dr. Houston brings more than 30 years of biotech and pharma drug development and...

| By Kelley Gipson

BioCT Launches New England Edge Purchasing Program

Introducing New England Edge, our new, exclusive purchasing program powered by MassBio. As a dedicated supporter of Connecticut’s bioscience industry, BioCT is constantly evaluating the...

| By Kelley Gipson

Europe approves Alexion SOLIRIS® treatment

Alexion Pharmaceuticals reports that the European Commission has approved the extension of the current marketing authorization of SOLIRIS® (eculizumab) to include the treatment of neuromyelitis optica...